Paitent taking medication within 2 weeks of starting covid-19 Treatment; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Paitent taking medication within 2 weeks of starting covid-19 Treatment) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Autoimmune disorder, Connective tissue disorder and Drug allergy.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In May 2022, the patient experienced COVID-19 (Paitent taking medication within 2 weeks of starting covid-19 Treatment). At the time of the report, COVID-19 (Paitent taking medication within 2 weeks of starting covid-19 Treatment) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication reported Moderna. No Treatment medication reported.  Event Dysgeusia subsumed under event event COVID-19.   Patient took Pfizer vaccine for Treatment of COVID-19 on 18-MAY-2022 and Date of last administration was 23-MAY-2022.  Company Comment:  This is a spontaneous case concerning a 75-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19, in the context of the third dose of mRNA-1273 vaccine. Latency cannot be properly assessed since vaccination date nor the exact event onset date were provided. Patient had received 2-dose primary series of mRNA-1273 vaccine on unknown dates with no reported adverse event, prior to third mRNA-1273 vaccination. Patient was given a six-day-course of COVID-19 treatment and noted nasty bitter taste in mouth, one day after initiation of the COVID-19 treatment. No further details about the diagnostic procedures and specific treatments were provided. Outcome of the event COVID-19 was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 75-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19, in the context of the third dose of mRNA-1273 vaccine. Latency cannot be properly assessed since vaccination date nor the exact event onset date were provided. Patient had received 2-dose primary series of mRNA-1273 vaccine on unknown dates with no reported adverse event, prior to third mRNA-1273 vaccination. Patient was given a six-day-course of COVID-19 treatment and noted nasty bitter taste in mouth, one day after initiation of the COVID-19 treatment. No further details about the diagnostic procedures and specific treatments were provided. Outcome of the event COVID-19 was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report.